Why and when to use this therapy to treat patients who have type 2 diabetes.
Read More »An SGLT-2 inhibitor Shows Renoprotective Benefits
Subanalysis of CANVAS program shows slower progression of kidney disease, reduction in weight, reduction in A1c and even drop in blood pressure.
Read More »Empagliflozin Reduces Cardiovascular Mortality
Most important mediator due to changes in markers of plasma volume.
Read More »Benefit of Canagliflozin In Patients with Type 2 Diabetes
Canagliflozin is found to have reduced risk of cardiovascular death or hospitalization due to heart failure in type 2 diabetes patients.
Read More »Yehuda Handelsman Part 2, Prescribing SGLT 2 Inhibitors
In part 2 of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the actual cost to the lives of patients who are put on more expensive, but life-saving, diabetes drugs.
Read More »Behind Empagliflozin’s Reduction in Cardiovascular Mortality
Post-hoc analysis of the breakthrough EMPA-REG Outcome trial demonstrated reduction in composite cardiovascular outcomes that can be seen with empagliflozin therapy.
Read More »Lower Death Risk with SGLT2 Inhibitors in Patients with Type 2 Diabetes
It is unclear whether SGLT2i show reduction in mortality in all patients with type 2 or just in patients with type 2 diabetes with increased cardiovascular risk.
Read More »Study Explores Mechanisms Behind Cardiovascular Benefits of SGLT2 inhibitors
Researchers complete examination of class of type 2 medication.
Read More »What You Need to Know About SGLT2i Use in Obesity
Therapy offers beneficial weight loss in treatment of diabetes, but which agent in the class leads to the greatest body weight reduction?
Read More »Jim McDermott Current Interview
Dr. Jim McDermott is Vice President of US Medical Affairs for Diabetes at AstraZeneca. He has been with AstraZeneca for more than two decades.
Read More »